IGC Pharma (IGC) Cash from Operations (2010 - 2025)
IGC Pharma (IGC) reported Cash from Operations of 2090000.0 for Q3 2025, down 109.84% year-over-year from 21241224.49 in Q3 2024, and down 48.54% quarter-over-quarter from 1407000.0 in Q2 2025.
IGC Pharma (IGC) Cash from Operations (2010 - 2025) Analysis & Trends
IGC Pharma (IGC) has 16 years of Cash from Operations data on file, last reported at 2090000.0 in Q3 2025.
- Cash from Operations for Q3 2025 came in at 2090000.0, down 109.84% year-over-year; the trailing twelve-month figure through Sep 2025 was 5544000.0 (down 14.05% YoY), and the FY2026 annual result was 1223000.0, up 74.49% from the prior year.
- Cash from Operations declined to 2090000.0 in Q3 2025 per IGC's latest filing, from 1407000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 526000.0 in Q1 2024 and troughed at 2505000.0 in Q1 2021.
- A 5-year average of 1605526.32 and a median of 1618000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2024 and 2025: Cash from Operations jumped 65.33% in 2024, then tumbled 109.84% in 2025.
- A 5-year view of Cash from Operations shows it stood at 2422000.0 in 2021, then jumped by 31.96% to 1648000.0 in 2022, then advanced by 3.7% to 1587000.0 in 2023, then rose by 17.01% to 1317000.0 in 2024, then slumped by 58.69% to 2090000.0 in 2025.
- Business Quant data shows IGC's Cash from Operations at 2090000.0 in Q3 2025, 1407000.0 in Q2 2025, and 730000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | IGC Pharma | 29.33 Mn | 29.07 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -2.09 Mn |
| Sep 30, 2025 | -2.09 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Jun 30, 2025 | -1.41 Mn |
| Mar 31, 2025 | -730,000.00 |
| Mar 31, 2025 | -730,000.00 |
| Dec 31, 2024 | -1.32 Mn |
| Dec 31, 2024 | -1.32 Mn |
| Sep 30, 2024 | -996,000.00 |
| Sep 30, 2024 | -996,000.00 |
| Jun 30, 2024 | -1.75 Mn |
| Jun 30, 2024 | -1.75 Mn |
| Mar 31, 2024 | -526,000.00 |
| Mar 31, 2024 | -526,000.00 |
| Dec 31, 2023 | -1.59 Mn |
| Dec 31, 2023 | -1.59 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Sep 30, 2023 | -1.62 Mn |
| Jun 30, 2023 | -1.47 Mn |
| Jun 30, 2023 | -1.47 Mn |